Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20526762 | 1.00 | MDM4 (0.52) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL20526765 | 1.00 | MDM4 (0.52) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL20526778 | 0.89 | MDM2 (0.49) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL20526634 | 0.89 | MDM4 (0.47) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL20526635 | 0.89 | MDM4 (0.47) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL20526770 | 0.89 | MDM4 (0.47) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL20526767 | 0.89 | MDM4 (0.47) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL20526779 | 0.89 | MDM2 (0.49) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL20526746 | 0.87 | MDM4 (0.46) | MDM4TP53SLC17A5MDM2CASP3 | |
| SCHEMBL20526625 | 0.87 | MDM2 (0.51) | MDM4TP53SLC17A5MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | BACOBA AG (CH) | 2026-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | NGLY1, MC1R, EGFR | MDM4 2280/4885TP53 190/4885SLC17A5 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.